Climb Bio Inc (CLYM)

Climb Bio Inc (CLYM) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $592M; returns 1 day -3.3%, 1 week +3.8%, 1 year +412.1%.

Climb Bio, Inc. (CLYM) is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Their lead product candidate is budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell mediated diseases.

Groups CLYM belongs to

• Biotechnology
• Clinical Stage Biotech
• Healthcare
• Monoclonal Antibodies
• Autoimmune Diseases
• Clinical Stage
• Life Sciences
• Biopharmaceutical
• Nephrology
• Chronic Inflammatory Diseases
• Antibody Therapeutics

CLYM financial model: income statement, cash flow and balance sheet